Healthcare
•3753 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3753)
| Company | Market Cap | Price |
|---|---|---|
|
IPHA
Innate Pharma S.A.
Lacutamab and monalizumab are monoclonal antibodies, aligning with Monoclonal Antibody Therapeutics.
|
$146.12M |
$1.75
-0.85%
|
|
BDTX
Black Diamond Therapeutics, Inc.
BDTX operates as a biotechnology company focused on oncology therapeutics, i.e., Biotech - Oncology.
|
$145.75M |
$2.56
-3.93%
|
|
USGO
U.S. GoldMining Inc.
Metallurgical testwork and related lab analyses are conducted to inform processing and PEA.
|
$145.60M |
$11.39
+1.56%
|
|
MRSN
Mersana Therapeutics, Inc.
Mersana is an oncology-focused biotechnology company with Emi-Le and XMT-2056 in clinical development.
|
$145.13M |
$29.10
+0.07%
|
|
NKTX
Nkarta, Inc.
Nkarta is developing allogeneic CAR NK cell therapy (NKX019) for autoimmune diseases, directly fitting the Cell Therapy product category.
|
$144.89M |
$2.05
+4.59%
|
|
PLX
Protalix BioTherapeutics, Inc.
Protalix manufactures recombinant proteins/enzymes (e.g., Elelyso, Elfabrio) using its plant-based ProCellEx system.
|
$143.52M |
$1.82
+1.39%
|
|
LNSR
LENSAR, Inc.
Direct ophthalmic device product (Ophthalmology Devices) produced by LENSAR via the ALLY robotic cataract laser system.
|
$142.02M |
$12.07
+0.67%
|
|
MCRB
Seres Therapeutics, Inc.
SER-155 is a cultivated live biotherapeutic product (cell therapy) comprising a defined bacterial consortium.
|
$139.72M |
$16.02
+5.50%
|
|
PDEX
Pro-Dex, Inc.
Direct product: the company manufactures surgical instruments (autoclavable, battery-powered multi-function handpieces and shavers).
|
$137.75M |
$41.96
+0.55%
|
|
CVRX
CVRx, Inc.
CVRx's Barostim is a neuromodulation device (implantable) that modulates the autonomic nervous system via baroreflex activation for heart failure.
|
$136.25M |
$5.20
-4.94%
|
|
IMMX
Immix Biopharma, Inc.
Directly categorizes the company’s lead product as a CAR-T cell therapy (cell therapy).
|
$135.52M |
$4.72
+0.21%
|
|
ELTX
Elicio Therapeutics, Inc.
Lead product candidate is a cancer vaccine/immunotherapy, aligning with Vaccines.
|
$134.79M |
$8.34
+6.79%
|
|
ACTU
Actuate Therapeutics Inc
Actuate Therapeutics is a biotech company focused on oncology with a lead product elraglusib (a GSK-3β inhibitor).
|
$134.64M |
$6.27
-3.39%
|
|
ANIK
Anika Therapeutics, Inc.
Company develops and sells orthopedic devices including implants for cartilage repair and related regenerative solutions.
|
$134.23M |
$9.32
-2.15%
|
|
ORMP
Oramed Pharmaceuticals Inc.
Oramed's POD platform constitutes the core drug-delivery technology enabling oral administration of therapeutic proteins (e.g., oral insulin).
|
$134.08M |
$3.37
+3.06%
|
|
CNTB
Connect Biopharma Holdings Limited
Lead asset CBP-201 (rademikibart) is a monoclonal antibody targeting IL-4Rα, directly fitting Monoclonal Antibody Therapeutics.
|
$131.50M |
$2.35
-0.42%
|
|
IXHL
Incannex Healthcare Limited
Incannex develops oral small-molecule therapeutics as fixed-dose drug combinations (IHL-42X).
|
$131.08M |
$0.38
-1.05%
|
|
SPRO
Spero Therapeutics, Inc.
Tebipenem HBr is an oral small-molecule antibiotic, which is the lead product and central to Spero’s current business focus.
|
$130.56M |
$2.33
-0.64%
|
|
ABOS
Acumen Pharmaceuticals, Inc.
Sabirnetug is a recombinant humanized IgG2 monoclonal antibody targeting soluble AßOs.
|
$129.63M |
$2.15
+9.69%
|
|
NIKA
Nika Pharmaceuticals Inc.
ITV-1 HIV therapeutic concept and related immunomodulatory platform sit within Biotech - Immunology Therapeutics.
|
$129.39M |
$0.38
|
|
CNTX
Context Therapeutics Inc.
The company's pipeline centers on T cell engaging bispecific antibodies (CTIM-76, CT-95, CT-202).
|
$129.17M |
$1.44
-5.59%
|
|
ELDN
Eledon Pharmaceuticals, Inc.
Tegoprubart is an IgG1 monoclonal antibody therapeutic targeting CD40L.
|
$126.95M |
$2.11
+1.93%
|
|
IRD
Opus Genetics, Inc.
Core product area: AAV-based gene therapies for inherited retinal diseases (OPGx-LCA5, OPGx-BEST1).
|
$125.81M |
$2.11
+1.44%
|
|
STIM
Neuronetics, Inc.
NeuroStar Advanced Therapy System is a non-invasive neuromodulation device; the direct product of the company.
|
$125.64M |
$1.90
+4.97%
|
|
IKT
Inhibikase Therapeutics, Inc.
IKT's lead program IKT-001Pro is an oral small-molecule therapeutic prodrug, fitting the 'Oral Small Molecule Therapeutics' investable theme.
|
$124.44M |
$1.68
+1.52%
|
|
RLMD
Relmada Therapeutics, Inc.
NDV-01 is Relmada's lead oncology candidate targeting non-muscle invasive bladder cancer (NMIBC).
|
$124.14M |
$3.75
-1.45%
|
|
ATRA
Atara Biotherapeutics, Inc.
Atara focuses on tab-cel (Ebvallo), an allogeneic T-cell therapy.
|
$123.46M |
$17.70
+0.71%
|
|
FONR
FONAR Corporation
Core product offering is the Upright MRI hardware, a specialized medical imaging platform.
|
$122.73M |
$18.62
-0.11%
|
|
LUCD
Lucid Diagnostics Inc.
EsoCheck is a diagnostic collection device used to obtain esophageal cells for testing, aligning with Diagnostic Equipment.
|
$122.58M |
$1.15
+1.33%
|
|
SGMO
Sangamo Therapeutics, Inc.
Core platform enabling genomic medicine via gene therapy and genome regulation (ZF/ZFR) technology.
|
$121.11M |
$0.39
-8.44%
|
|
AVHHL
AVITA Medical, Inc.
AVITA Medical’s core offerings are wound care devices and dermal matrices (RECELL system, RECELL GO, PermeaDerm, Cohealyx) used in wound management, fitting the Wound Care Devices category.
|
$119.99M |
$0.79
|
|
TNYA
Tenaya Therapeutics, Inc.
Tenaya's lead programs TN-201 and TN-401 are gene therapies (AAV-based) targeting genetic heart diseases.
|
$118.89M |
$0.72
-2.17%
|
|
STRO
Sutro Biopharma, Inc.
Directly represents Sutro's core assets: Antibody-Drug Conjugates (ADC) programs using the XpressCF+ platform.
|
$117.16M |
$13.72
+4.97%
|
|
FATE
Fate Therapeutics, Inc.
Fate develops oncology-focused immunotherapies, aligning with Biotech - Oncology.
|
$116.48M |
$1.01
|
Showing page 24 of 38 (3753 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
